

SAFETY DATA SHEET

SECTION 1 : IDENTIFICATION

Product Name: Dexamethasone Sodium Phosphate Injection, USP Simplist™ 4mg/mL
Manufacturer Name: Fresenius Kabi Simplist™
Address: Three Corporate Drive
 Lake Zurich, Illinois 60047
General Phone Number: (847) 550-2300
SDS Creation Date: March 18, 2016
SDS Revision Date: March 18, 2016

SECTION 2 : HAZARD(S) IDENTIFICATION

GHS Pictograms:



Signal Word: DANGER.

GHS Class: Respiratory sensitisation. Category 1.
 Skin Sensitization. Category 1.
 Acute Oral Toxicity. Category 4.
 Reproductive toxicity. Effects on or via lactation.

Hazard Statements: May cause allergy or asthma symptoms or breathing difficulties if inhaled.
 May cause an allergic skin reaction.
 Harmful if swallowed.
 May cause harm to breast-fed children.

Precautionary Statements: Obtain special instructions before use.
 Do not breathe dust/fume/gas/mist/vapours/spray.
 Avoid breathing dust/fume/gas/mist/vapours/spray.
 Avoid contact during pregnancy and while nursing.
 Wash hands thoroughly after handling.
 Do not eat, drink or smoke when using this product.
 Contaminated work clothing should not be allowed out of the workplace.
 Wear protective gloves/protective clothing/eye protection/face protection.
 In case of inadequate ventilation wear respiratory protection.
 IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell.
 IF ON SKIN: Wash with plenty of water.
 IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing.
 IF exposed or concerned: Get medical advice/attention.
 Rinse mouth.
 If skin irritation or rash occurs: Get medical advice/attention.
 If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician.
 Take off contaminated clothing and wash it before reuse.
 Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations.

Potential Health Effects: This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.

SECTION 3 : COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS#	Ingredient Percent	EC Num.
Dexamethasone Phosphate	2392-39-4	0.4 - 1 by weight	
Notes : Nonhazardous ingredients include Water for Injection and Sodium citrate. Sodium hydroxide may be added to adjust the pH.			

SECTION 4 : FIRST AID MEASURES

Eye Contact: Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of the eyes by separating the eyelids with fingers. Get immediate medical attention.

Skin Contact: Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes.
 Get medical attention if irritation develops or persists.

Inhalation: If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention.

Ingestion: If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.

SECTION 5 : FIRE FIGHTING MEASURES

Flash Point:	Not established.
Flash Point Method:	Not established.
Auto Ignition Temperature:	Not established.
Lower Flammable/Explosive Limit:	Not established.
Upper Flammable/Explosive Limit:	Not established.
Fire Fighting Instructions:	Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible, contain fire run-off water.
Extinguishing Media:	Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires involving this material. Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Protective Equipment:	As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear.
Hazardous Combustion Byproducts:	Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of combustion.

SECTION 6 : ACCIDENTAL RELEASE MEASURES

Personal Precautions:	Evacuate area and keep unnecessary and unprotected personnel from entering the spill area. Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as listed in Section 8.
Environmental Precautions:	Avoid runoff into storm sewers, ditches, and waterways.
Methods for containment:	Contain spills with an inert absorbent material such as soil, sand or oil dry.
Methods for cleanup:	Absorb spill with inert material (e.g., dry sand or earth), then place in a chemical waste container. After removal, flush spill area with soap and water to remove trace residue.

SECTION 7 : HANDLING and STORAGE

Handling:	When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions.
Storage:	Store at controlled room temperature 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature]. Sensitive to heat. Do not autoclave. Protect from freezing. Protect from light.
Work Practices:	Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.
Hygiene Practices:	Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

Engineering Controls:	General ventilation is sufficient if this product is being used in a controlled medical setting (clinic, hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended exposure limits.
Eye/Face Protection:	Chemical splash goggles. Wear a face shield also when splash hazard exist.
Skin Protection Description:	Protective laboratory coat, apron, or disposable garment recommended.
Hand Protection Description:	Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data. Nitrile rubber or natural rubber gloves are recommended.
Respiratory Protection:	No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site (http://www.cdc.gov/niosh/npptl/topics/respirators/) for a list of respirator types and approved suppliers.
Other Protective:	Consult with local procedures for selection, training, inspection and maintenance of the personal protective equipment.

EXPOSURE GUIDELINES

SECTION 9 : PHYSICAL and CHEMICAL PROPERTIES

Physical State:	Liquid solution.
Color:	Colorless.

Odor:	Odorless.
Odor Threshold:	No information.
Boiling Point:	Approximately that of water, 100°C (212°F)
Melting Point:	Approximately that of water, 0°C (32°F)
Specific Gravity:	1.0045
Solubility:	Soluble. in water.
Vapor Density:	Not established.
Vapor Pressure:	Not established.
Percent Volatile:	Not established.
pH:	7.0 - 8.5
Flash Point:	Not established.
Flash Point Method:	Not established.
Auto Ignition Temperature:	Not established.

SECTION 10 : STABILITY and REACTIVITY

Chemical Stability:	Stable under normal temperatures and pressures.
Hazardous Polymerization:	Not reported.
Conditions to Avoid:	Protect from light and excessive heat. Do not autoclave. Do not freeze.

SECTION 11 : TOXICOLOGICAL INFORMATION

Acute Toxicity:	ACUTE EFFECTS: In the event of an overdose, no specific antidote is available. Treatment is supportive and symptomatic.
-----------------	---

Dexamethasone Phosphate :

Acute Toxicity:	LD50: IV Female Mouse 794 mg/kg
-----------------	---------------------------------

Acute Effects:	In the event of an overdose, no specific antidote is available. Treatment is supportive and symptomatic.
----------------	--

Chronic Effects:	Prolonged exposure may result in subcapsular cataracts, glaucoma, hypertension, salt and water retention, and hypokalemia.
------------------	--

Dexamethasone Phosphate :

RTECS Number:	TU4056000
---------------	-----------

Ingestion:	Oral - Mouse LD50: 1800 mg/kg [Details of toxic effects not reported other than lethal dose value]
------------	--

Mutagenicity:	Dexamethasone has been found to be negative in the bacterial reverse mutation assay and positive/equivocal in the in vivo chromosomal aberration and micronucleus assays. Dexamethasone has been found to induce apoptosis, which may confound the findings of some genetic toxicology assays. Hence dexamethasone can be considered a non-genotoxic apoptosis inducer.
---------------	---

Reproductive Toxicity:	Studies in pregnant animals have shown dexamethasone to be teratogenic and to induce maternal toxicity. Specifically, cleft palate has been identified in mice and rabbits treated with dexamethasone and resorption rates were increased and fetal weights were decreased in exposed animals.
------------------------	--

Teratogenicity:	Pregnancy Category C. Use of dexamethasone sodium phosphate in pregnancy requires that the anticipated benefits be weighed against the potential risks to the mother and fetus.
-----------------	---

Other Toxicological Information:	Intraperitoneal - Rat TDLo - Lowest published toxic dose: 1 mg/kg [Vascular - BP elevation not characterized in autonomic section] Intraperitoneal - Rat (Female.19-20days(s) after conception) TDLo - Lowest published toxic dose: 400 ug/kg [Reproductive - Effects on Newborn - growth statistics (e.g.,%, reduced weight gain)] Intraperitoneal - Mouse LD50 - Lethal dose, 50 percent kill: 550 mg/kg [Details of toxic effects not reported other than lethal dose value] Intraperitoneal - Mouse TDLo - Lowest published toxic dose: 0.2 mg/kg [Gastrointestinal - Other changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - Other enzymes Biochemical - Metabolism (intermediary) - Histamines (including liberation not immunochemical in origin)] Intravenous - Mouse LD50 - Lethal dose, 50 percent kill: 932 mg/kg [Details of toxic effects not reported other than lethal dose value] Subcutaneous - Rat TDLo - Lowest published toxic dose: 100 mg/kg/10D (Intermittent) [Endocrine - Diabetes mellitus Nutritional and Gross Metabolic - Weight loss or decreased weight gain Biochemical - Metabolism (intermediary) - Lipids including transport] Subcutaneous - Rat TDLo - Lowest published toxic dose: 100 mg/kg/10D (Intermittent) [Endocrine - Diabetes mellitus Blood - Changes in serum composition (e.g., TP, bilirubin, cholesterol) Biochemical - Metabolism (intermediary) - Lipids including transport] Subcutaneous - Rat TDLo - Lowest published toxic dose: 5 mg/kg/2W (Intermittent) [Cardiac - Other changes Vascular - BP elevation not characterized in autonomic section Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - Proteases] Subcutaneous - Mouse (Female.11-14days(s) after conception) TDLo - Lowest published toxic dose: 12800 ug/kg [Reproductive - Fertility - post-implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - Craniofacial (including nose and tongue)] (RTECS)
----------------------------------	--

SECTION 12 : ECOLOGICAL INFORMATION

Ecotoxicity:	No ecotoxicity data was found for the product.
--------------	--

Environmental Stability: No environmental information found for this product.

SECTION 13 : DISPOSAL CONSIDERATIONS

Waste Disposal: Dispose of in accordance with Local, State, Federal and Provincial regulations.

SECTION 14 : TRANSPORT INFORMATION

DOT Shipping Name: Not Regulated.

DOT UN Number: Not Regulated.

SECTION 15 : REGULATORY INFORMATION

Dexamethasone Phosphate :

TSCA Inventory Status: Listed

EINECS Number: 219-243-0

Canada DSL: Listed

SECTION 16 : ADDITIONAL INFORMATION

HMIS Ratings:

HMIS Health Hazard: 1

HMIS Fire Hazard: 1

HMIS Reactivity: 1

HMIS Personal Protection: X

SDS Creation Date: March 18, 2016

SDS Revision Date: March 18, 2016

Copyright© 1996-2015 Actio Corporation. All Rights Reserved.